EORTC 26101 – Phase III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.
Phase II trial exploring the sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.
EORTC study comparing two treatment regimens in patients with reoccurring glioblastoma (GBM), found that the combination treatment of bevacizumab and lomustine, did not provide additional survival benefit for those patients. The MRI images however collected in this trial, were analyzed using an automated quantitative tumour response assessment, called artificial neural networks (ANN). The study showed that using ANN, enabled objective, uniform, and automated assessment of tumour response that helps overcome the limitations of manual, human assessment of MRI images. This study could ultimately serve as a blueprint for the application of ANN in radiology to improve clinical decision making and tumor assessment.